世界最富華裔醫生在洛杉磯的財富版圖
LOS ANGELES — Dr. Patrick Soon-Shiong, the new vice chairman andsecond-largest investor in Tribune Publishing, is believed to be the wealthiest physician in the world and the richest person in this city, surpassing all the Hollywood moguls.
洛杉磯——黃馨祥博士(Patrick Soon-Shiong)成爲論壇出版公司(Tribune Publishing)的新副主席和第二大投資者。他被認爲是世界上最富有的醫生和洛杉磯首富，超過所有的好萊塢巨頭。
Much of that fortune, valued at $11.9 billion by Forbes, came from selling generic drugs and from developing one new Type of drug to treat cancer.
據《福布斯》(Forbes)估算，他的資產總額爲119億美元。大部分來自銷售非專利藥以及一種新型抗癌藥的研發。
But his meteoric rise has not been without controversy, either, as he has developed a reputation for exaggerating his prospects and accomplishments.
不過，他的迅速崛起並非沒有引起爭議，因爲他以誇大自己的前景和成就聞名。
“He thinks big and sometimes his statements come off hyperbolic,” said Dr. Eric Topol, professor of genomics at the Scripps Research Institute. “Only time will tell” how much he really accomplishes, Dr. Topol said.
“他總想幹一番大事，有時他的敘述顯得很誇張，”斯克裏普斯研究所(Scripps Research Institute)的基因組學教授埃裏克·託波爾博士(Eric Topol)說。託波爾說，“時間會證明”他到底做出了多少成就。
In a brief interview Monday, Dr. Soon-Shiong said he did not see his $70.5 million investment in Tribune Publishing, which owns The Los Angeles Times and The Chicago Tribune, as a philanthropic exercise. But he said he did consider newspapers a “public trust” and wanted to preserve them.
週一，黃馨祥在接受簡短採訪時說，他不認爲自己向論壇出版公司注資7050萬美元是做慈善。論壇出版公司擁有《洛杉磯時報》(The Los Angeles Times)和《芝加哥論壇報》(The Chicago Tribune)。不過，他說，他的確認爲報紙是“公益信託”，他想要保護報紙。
Dr. Soon-Shiong (pronounced Soon Shung) said he appreciated the value of a free press after having grown up in apartheid-era South Africa, the son of immigrants from China.
馨祥博士說，作爲中國移民後代，他在種族隔離時代的南非長大，深知新聞自由的價值。
“I recognize the press is a very valuable tool for the community, where it really adds to democracy,” he said. He also said the investment could make money if Tribune could be transformed from a “legacy newspaper company” into a technology and content company.
“我認識到，報界對社會來說是很有價值的工具，它真的能促進民主，”他說。他還說，如果論壇出版公司能從“傳統報業公司”轉變爲技術和內容公司，他的投資可能會獲得回報。
On politics, Dr. Soon-Shiong, 63, called himself the “quintessential independent.” He has donated $82,400 to campaigns, according to the Federal Election Commission, including $60,000 to the Democratic National Committee. But he has also donated to Rudolph Giuliani and Rick Perry, both Republicans.
在政治方面，63歲的馨祥博士稱自己是“典型的獨立派”。據聯邦選舉委員會(Federal Election Commission)稱，他總共爲競選捐款8.24萬美元，其中6萬捐給了民主黨全國委員會(Democratic National Committee)。不過，他也捐款給魯道夫·朱利亞尼(Rudolph Giuliani)和裏克·佩裏(Rick Perry)兩位共和黨人。
Dr. Soon-Shiong said it was his medical projects that got him involved with Tribune. His companies were developing artificial intelligence and machine vision — for such tasks as having a computer analyze pathology slides or helping the vision-impaired to navigate.
馨祥博士說，他是因爲自己的醫療項目而介入論壇出版公司的。當時他的公司在開發人工智能和機器視覺，比如電腦分析病理切片，或者給視覺障礙者指路。
Michael W. Ferro Jr., who is now the biggest shareholder in Tribune, had been an investor in a medical imaging company, Merge Healthcare, and came to see what Dr. Soon-Shiong had developed. Under a deal also announced Monday, Tribune will have access to that technology for use in the newspaper business, eventually paying royalties to one of Dr. Soon-Shiong’s companies.
小邁克爾·W·費羅(Michael W. Ferro Jr.)目前是論壇出版公司最大的股東，也是做醫學成像的融合醫療公司(Merge Healthcare)的一位投資人，他對馨祥博士所研發的技術進行了瞭解。依照週一公佈的另一項協議，論壇出版公司可以將這項技術用於報紙業務，最後向馨祥博士擁有的一家公司支付使用費。
One use, Dr. Soon-Shiong said, could be to point a phone camera at an article in the printed newspaper and have related video content pop up.
馨祥博士說，其中一項用途是把手機攝像頭對準紙質報紙上的一篇文章，相關的視頻就會彈出。
Taking a stake in the owner of The Los Angeles Times would not be out of character for Dr. Soon-Shiong. While not well known outside Los Angeles, he has taken an active role in institutions here.
馨祥博士成爲《洛杉磯時報》的股東並不出人意料。出了洛杉磯他不是很出名，但在當地的很多機構中都有他活躍的身影。
He is a part owner of the Los Angeles Lakers, buying Magic Johnson’s 4.5 percent stake. He made an unsuccessful bid to buy the Dodgers, losing out to a group that included Magic Johnson.
他從魔術師約翰遜(Magic Johnson)手中買下4.5%的股權，成爲洛杉磯湖人隊(Los Angeles Lakers)的所有者之一。他曾出價購買道奇隊(Dodgers)，但輸給了包括魔術師約翰遜在內的一個團體。
He and his wife, Michele Chan, an actress, have given at least $135 million to Saint John’s Health Center in Santa Monica, and he has helped reopen Martin Luther King Jr. Community Hospital, which serves impoverished South Los Angeles.
他和演員妻子米歇爾·陳(Michele Chan)至少向聖莫尼卡的聖約翰醫療中心(Saint John’s Health Center)捐款1.35億美元。他還幫助重新開放小馬丁·路德·金社區醫院(Martin Luther King Jr. Community Hospital)，爲洛杉磯南部的窮人服務。
After getting his medical degree in South Africa, Dr. Soon-Shiong became a doctor at the University of California, Los Angeles.
馨祥在南非獲得醫學學位後，在加州大學洛杉磯分校(University of California, Los Angeles)獲得博士學位。
In 1993, he made headlines for doing the first transplant of insulin-producing pancreatic cells into a patient with Type 1 diabetes. While he proclaimed that the procedure had succeeded, other experts questioned that claim.
1993年，他首次向I型糖尿病患者移植能產生胰島素的胰腺細胞，因此登上報紙頭條。雖然他宣告移植成功，但其他專家表示質疑。
He started a company selling generic drugs, taking advantage of a financial relationship with Premier, a group that buys drugs for hospitals. The company, APP Pharmaceuticals, was sold to the German company Fresenius for an initial payment $3.7 billion in 2008.
他開設了一家公司，名叫APP Pharmaceuticals，利用與Premier的金融關係，銷售非專利藥。Premier是一家爲醫院採購藥品的機構。2008年，德國公司弗雷澤紐斯(Fresenius)以37億美元的首付款買下APP Pharmaceuticals。
His biggest accomplishment was the development of the cancer drug Abraxane. It consists of the widely used drug paclitaxel (also known by the brand name Taxol) linked to particles of albumin, a protein in blood. That helps the drug get to the tumors better and makes the treatment more tolerable.
他最大的成就是開發出抗癌藥Abraxane。它包含被廣泛使用的藥物paclitaxel（品牌名爲紫杉酚[Taxol]）。Abraxane能把紫杉酚與血液中的蛋白質白蛋白分子連接起來，從而幫助這種藥物更好地到達腫瘤，讓治療過程更易忍受。
Doctors debate whether any advantages of Abraxane merit the extra cost compared with generic paclitaxel. But Celgene, the large biotechnology company, saw enough in Abraxane to acquire the company that controlled it for an initial payment of $2.9 billion in 2010.
醫生們質疑，與非專利藥紫杉酚相比，Abraxane的優勢是否值得爲之付出額外的成本。但是大型生物技術公司新基公司(Celgene)看重Abraxane，2010年以29億美元的首付款買下持有這種藥物的公司。
Dr. Soon-Shiong’s new project is NantWorks, an “ecosystem” of different companies aimed at medicine. “We like to think NantWorks is combing the inventive spirit of Thomas Edison or Leonardo da Vinci,” its website says. “All at the scale of Bell Labs.”
馨祥博士的新項目是NantWorks，它是一個由多家醫藥公司組成的“生態系統”。“我們認爲，NantWorks在搜尋托馬斯·愛迪生(Thomas Edison)或萊昂納多·達芬奇(Leonardo da Vinci)的發明精神，”NantWorks的網站說，“規模相當於貝爾實驗室(Bell Labs)。”
One company in the network, NantKwest, is developing cancer treatments that harness the body’s immune system. It went public last summer with an initial market value of $2.6 billion, a record for a biotechnology company. The stock has lost three-quarters of its value since then.
該系統中的一家公司NantKwest正在研發調節人體免疫系統的癌症治療法。去年夏天，這家公司上市，最初的市值爲26億美元，創下生物技術類公司的最高記錄。截至目前，它的市值已縮水四分之三。
Another company, privately held NantHealth, is trying to use DNA sequencing and high-powered computing to quickly analyze a patient’s genes and other medical information and suggest the best treatment. It has raised more than $600 million, including from the government of Kuwait.
還有一傢俬營公司NantHealth正嘗試利用DNA排序和高性能計算機快速分析病人的基因等醫療信息，提出最佳治療方案。它已籌資6億多美元，包括來自科威特政府的資金。
Two former executives filed a wrongful termination lawsuit accusing NantHealth of making fraudulent claims about the reliability of its technology. The company says the suit is without merit.
該公司的兩位前高管提出了一項不當解僱訴訟，指控NantHealth對自己技術的可靠性做出了欺騙性的陳述。公司方面則稱該指控毫無根據。
In January, Dr. Soon-Shiong announced a Cancer Moonshot 2020 program, in which companies like Celgene and Amgen would cooperate on certain clinical trials. He has also been an adviser to Vice President Joseph R. Biden Jr., though Mr. Biden’s cancer moonshot program is distinct from Dr. Soon-Shiong’s.
今年1月，馨祥博士宣佈啓動癌症登月計劃2020(Cancer Moonshot 2020)，新基(Celgene)和安進(Amgen)等公司將參與某些臨牀試驗。他也是副總統小約瑟夫·R·拜登(Joseph R. Biden Jr.)的顧問，雖然拜登的癌症登月計劃與馨祥的截然不同。
